HK56189A - Use of n-(diethylaminoethyl)-2-methoxy-5-methylsulfonyl benzamide for the inhibition of tryptophane pyrrolase - Google Patents

Use of n-(diethylaminoethyl)-2-methoxy-5-methylsulfonyl benzamide for the inhibition of tryptophane pyrrolase

Info

Publication number
HK56189A
HK56189A HK561/89A HK56189A HK56189A HK 56189 A HK56189 A HK 56189A HK 561/89 A HK561/89 A HK 561/89A HK 56189 A HK56189 A HK 56189A HK 56189 A HK56189 A HK 56189A
Authority
HK
Hong Kong
Prior art keywords
pyrrolase
inhibition
tiapride
diethylaminoethyl
methoxy
Prior art date
Application number
HK561/89A
Other languages
German (de)
English (en)
French (fr)
Inventor
Denis Dr. Besancon
Original Assignee
Societe D'etudes Scientifiques Et Industrielles De L'ile De France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe D'etudes Scientifiques Et Industrielles De L'ile De France filed Critical Societe D'etudes Scientifiques Et Industrielles De L'ile De France
Publication of HK56189A publication Critical patent/HK56189A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
HK561/89A 1982-06-17 1989-07-13 Use of n-(diethylaminoethyl)-2-methoxy-5-methylsulfonyl benzamide for the inhibition of tryptophane pyrrolase HK56189A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8210565A FR2528702A1 (fr) 1982-06-17 1982-06-17 Application du n-(diethylaminoethyl) 2-methoxy-5-methylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase

Publications (1)

Publication Number Publication Date
HK56189A true HK56189A (en) 1989-07-21

Family

ID=9275096

Family Applications (1)

Application Number Title Priority Date Filing Date
HK561/89A HK56189A (en) 1982-06-17 1989-07-13 Use of n-(diethylaminoethyl)-2-methoxy-5-methylsulfonyl benzamide for the inhibition of tryptophane pyrrolase

Country Status (8)

Country Link
US (1) US4485115A (enExample)
EP (1) EP0099775B1 (enExample)
JP (1) JPS5916823A (enExample)
AT (1) ATE22800T1 (enExample)
DE (2) DE3320187A1 (enExample)
FR (1) FR2528702A1 (enExample)
HK (1) HK56189A (enExample)
IT (1) IT1203657B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6245371A (ja) * 1985-08-24 1987-02-27 Toyota Motor Corp 車両ボデ−外板の塗装方法およびその装置
JPH0767544B2 (ja) * 1986-12-27 1995-07-26 トヨタ自動車株式会社 回転霧化静電塗装装置
EP0520325A1 (de) * 1991-06-28 1992-12-30 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch
EP1380292A1 (de) * 2002-07-03 2004-01-14 Mewicon med. wiss. Beratung GmbH Tiaprid zur Behandlung von Depressionen
US20040224031A1 (en) * 2003-05-06 2004-11-11 Antonio Zorzano Olarte Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
CN119384278A (zh) * 2022-06-10 2025-01-28 上海日馨医药科技股份有限公司 治疗精神类疾病的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791677A (fr) * 1972-07-19 1973-03-16 Renfag Sa Procede de preparation de n-(diethylaminoethyl)-2- methoxy-5-methylsulfonyl-benzamide
FR2243187B1 (enExample) * 1973-09-10 1978-12-29 Ile De France
FR2305176A1 (fr) * 1975-03-28 1976-10-22 Ile De France Nouveau medicament a base de n-(diethylaminoethyl) 2-methoxy-5-methyl-sulfonyl benzamide
JPS5283621A (en) * 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd N-benzyl-n, -benzylethyldiamine derivative

Also Published As

Publication number Publication date
JPS5916823A (ja) 1984-01-28
EP0099775A1 (fr) 1984-02-01
DE3320187A1 (de) 1983-12-22
ATE22800T1 (de) 1986-11-15
IT1203657B (it) 1989-02-15
IT8348506A0 (it) 1983-06-15
DE3366834D1 (en) 1986-11-20
FR2528702A1 (fr) 1983-12-23
US4485115A (en) 1984-11-27
FR2528702B3 (enExample) 1985-04-19
JPH0344050B2 (enExample) 1991-07-04
EP0099775B1 (fr) 1986-10-15

Similar Documents

Publication Publication Date Title
O'Reilly et al. Pharmacogenetic response to antidepressants in a multicase family with affective disorder
Poldrugo et al. The role of gamma-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies.
Lejoyeux et al. Benzodiazepine treatment for alcohol-dependent patients
AU576538B2 (en) A method of treating narcotic addiction
Veseli et al. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man
US5152994A (en) Rapid method for interrupting or attenuating poly-drug dependency syndromes
Oswald et al. Some experiments in the chemistry of normal sleep
HUE035105T2 (en) A composition comprising nicotine and opipramole and its use
US5426120A (en) Pharmaceutical composition containing γ-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
Rosecrans Effects of nicotine on behavioral arousal and brain 5-hydroxytryptamine function in female rats selected for differences in activity
JPS6323817A (ja) ブロモクリプチンの新用途
Dose et al. The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes
Ring et al. Vigabatrin: rational treatment for chronic epilepsy.
HK56189A (en) Use of n-(diethylaminoethyl)-2-methoxy-5-methylsulfonyl benzamide for the inhibition of tryptophane pyrrolase
Bazzari Can we induce lucid dreams? A pharmacological point of view
Leong et al. Acetylcholine and affective disorder
Gann et al. Polysomnography during withdrawal with clomethiazole or placebo in alcohol dependent patients-A double-blind and randomized study
Bunney Jr et al. Sleep and behavioral changes possibly reflecting central receptor hypersensitivity following catecholamine synthesis inhibition in man
Wang et al. Amyloban, extracted from Hericium erinaceus, ameliorates social deficits and suppresses the enhanced dopaminergic system in social defeat stress mice
Brengelmann et al. Effects of 5-hydroxytryptophan on schizophrenia
DOUST et al. Amines and aphrodisiacs in chronic schizophrenia
Yahr Parkinson's disease
Mittel Parkinson's disease: Overview and current abstracts
Markianos et al. Urinary noradrenaline and serotonin metabolites in drug‐free Parkinson patients and the effect of L‐dopa treatment
Murphy Treatment of Parkinsonism with laevodopa

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)